Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Oct 26, 2023 9:49am
121 Views
Post# 35701889

RE:1$US

RE:1$USFinally the Levesque era is a disaster. He failed on everything he was supposed to bring to the company. Sure we can say covid did not help, we can also say that he inherited a big debt, but he was supposed to be the guy that would raise revenues and allow to reimburse it without dilution. He failed at signing any partnership. He failed in making sure the company would be able to run a proper phase I trial in a reasonable delay with the right protocol. He spnt like a drunken sailor and hired employees like he was still at Pfizer. So we are where we are today. Given how bad the situation was I would be willing to accept the dilution if it would mean finally achieving some real success that would propel the stock price much higher, but who in the diluted shareholders are now trusting him and his team and the board to be the ones able achieve that? Why can we think that they won't waste this new money ans achieve nothing else. Also they were misleading in their public statements about avoiding dilution and concentrate on paying the debt. Finally it's the old shareolders that are paying this debt with a dilution of their investment. As for Levesque, why is he still CEO of this company with his mounstruous salary? At this point it is impossible to understand. He lost all credibility.
<< Previous
Bullboard Posts
Next >>